|Bid||7.84 x 800|
|Ask||7.88 x 1300|
|Day's Range||7.79 - 8.14|
|52 Week Range||4.65 - 8.69|
|Beta (3Y Monthly)||3.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.75|
Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,222,500 shares of common stock at the public offering price. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies. The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.
Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering pursuant to Fluidigm’s existing shelf registration statement. Piper Jaffray and UBS Investment Bank are acting as joint book-running managers for the offering. A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 8, 2017, amended on April 28, 2017 and declared effective by the SEC on May 2, 2017. The offering will be made only by means of a written prospectus and prospectus supplement.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s.
Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of November 6, 2018, under Fluidigm's 2017 Inducement Award Plan (Plan), as a material inducement to 16 individuals entering into employment with Fluidigm. In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 123,729 restricted stock units (RSU Awards) and options to purchase 58,949 shares of common stock (Option Awards).
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 -- Fluidigm Corporation.
Designed as people’s choice awards, LSIA has been a tradition in the life science industry for 15 years. Recipients are selected based on responses from thousands of scientists who are members of The Science Advisory Board, the world’s largest market research panel of scientific customers.
Fluidigm (FLDM) delivered earnings and revenue surprises of 0.00% and 5.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 38 cents. The company that makes equipment to control fluids posted revenue of $29 million in the period, topping ...
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO,.
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 -- Sirona.
Fluidigm Corporation (FLDM) today announced the appointment of Laura M. Clague to the company’s Board of Directors and its audit committee. Clague is Chief Financial Officer of Retrophin, Inc., with more than 30 years of experience as a senior financial executive. Clague has served as CFO at Retrophin since 2014, overseeing its accounting, finance, IT and facilities functions.
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25,.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a non-exclusive distribution agreement with DNA.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2018-- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced two new total RNA sequencing applications for the C1™ system. ...